Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 15, 2014

Dignify Receives SBIR Award for Bladder and Bowel Therapy

  • Dignify Therapeutics was awarded a $159,000  phase I Small Business Innovation Research (SBIR) grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health (NIH).  

    Dignify is focused on restoring bladder and bowel control to people with spinal injury, spina bifida, and other neurological conditions with the aim of improving the quality-of-life for individuals that rely on bladder catheters and bowel programs for voiding. 

    “These funds will support the ongoing development of our lead product candidate, DTI-100, through the IND approval process and into clinical trials,” said Karl Thor, president and CSO.  “This SBIR award, together with future non-dilutive funding, will augment the Company’s current efforts to raise up to $3 million from private investors to develop DTI-100 through Phase II clinical trials.”   



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »